ArriVent's furmonertinib fails key lung cancer trial endpoint
ArriVent BioPharma's oral lung cancer drug furmonertinib failed to significantly delay tumor progression versus chemotherapy in a late-stage study, missing its primary endpoint despite a modest numerical benefit and triggering a sharp drop in the company's share price.
ArriVent BioPharma's experimental lung cancer treatment furmonertinib failed its main goal in a late-stage study. The company's shares fell more than 50% in pre-market trading Tuesday after the drug did not meaningfully delay tumor progression compared to chemotherapy, with the results missing statistical significance.
Clinical details and comparative benefit
Although the primary endpoint was not met, a trend toward a survival benefit was observed. No new safety signals were identified with furmonertinib. The highest dose showed a median 1.5-month improvement in progression-free survival over chemotherapy.
| Treatment Arm | Median Progression-Free Survival |
|---|---|
| Furmonertinib (highest dose) | 11 months |
| Chemotherapy | 9.5 months |
ArriVent reported this 1.5-month benefit, with the highest dose of furmonertinib delaying tumor progression by a median of 11 months versus 9.5 months for chemotherapy.
Therapeutic context and unmet need
Furmonertinib is being evaluated as a first-line oral monotherapy for lung tumors with EGFR exon 20 insertion mutations. These mutations affect up to 10% of non-small cell lung tumors and currently have limited approved treatment options. Johnson & Johnson's Rybrevant and Takeda's Exkivity were the first marketed treatments targeting this mutation, but Exkivity was withdrawn. Rybrevant is an intravenously administered biologic. ArriVent tested furmonertinib as a monotherapy against chemotherapy, not in combination.
Industry landscape and missed opportunity
Success in the study would have opened a market opportunity for ArriVent to challenge other EGFR exon 20 insertion mutation treatments. Their therapy showed an effect on tumor progression that surpassed historical benchmarks. The monotherapy strategy could have led to a regimen with fewer side effects, according to analysts. However, the trial fell short of the three-month PFS improvement analysts had anticipated. Jefferies analyst Roger Song wrote in a note to investors last month that "his team was looking to see a three-month improvement over chemotherapy in progression-free survival."
Company response and external validation
ArriVent's CEO Bing Yao said "the company will evaluate the data to determine the next steps for furmonertinib." The competitive landscape continues to evolve. Taiho Oncology and Cullinan Therapeutics have a partnership that recently posted a victory in first-line disease and surpassed historical benchmarks on tumor progression. Separately, AstraZeneca agreed to pay up to $1.5 billion for rights to a marketed therapy from Dizal Pharma. ArriVent will evaluate the data to determine the next steps for furmonertinib.
